International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases
International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases
International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and Future Clinical Trials
Stem Cells Market to reach US$270.5 bn by 2025, globally: Transparency Market Research
International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical Trial
STEMCELL Technologies Signs Exclusive License with Propagenix to Commercialize EpiX, an Innovation Empowering Epithelial Cell Biology and Cell Therapy
U.S. Stem Cell, Inc. Reports Debt Restructuring Agreement and Debt Reduction in Form 8-K
U.S. Stem Cell, Inc. Corporate Office, Lab, and Clinic Remain Operational Post Hurricane Irma
International Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinson's Disease
Brinker International Names Joseph Taylor As Chief Financial Officer
 52   53   54   55   56     57    58   59   60   61   62 
 <<   <   >   >>